OOIR: Observatory of International Research

Papers

(The H4-Index of Best Practice & Research Clinical Endocrinology & Metabolism is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Editorial Board	152
Editorial Board	92
Growth hormone replacement in adults with cured acromegaly: Efficacy and safety	74
Editorial Board	69
Recent progress in molecular classification of phaeochromocytoma and paraganglioma	64
Treatment of acromegaly with the nonpeptide, highly selective somatostatin receptor type 2 agonist paltusotine	62
Gonadectomy in individuals with a difference of sex development – For whom, when, why, and why not?	57
Surgery for prolactinoma	56
Thiazide-induced hyponatremia	54
The role of androgens in transgender medicine	45
Sexual health and contraception in the menopause journey	44
Polygenic risk scores for dyslipidemia and atherosclerotic cardiovascular disease: Progress toward clinical implementation	42
Coronavirus disease 2019 and vitamin D	39
Editorial Board	36
Impulse control disorders and dopamine agonists	35
Editorial Board	34
Cardiometabolic outcomes of early onset hypogonadism in males	34
Remnant lipoprotein particles and cardiovascular disease risk	33
Haematological actions of androgens	31
Optimal surgical approach for digestive neuroendocrine neoplasia primaries: Oncological benefits versus short and long-term complications	31
Radioiodine therapy in the different stages of differentiated thyroid cancer	27
Medullary thyroid cancer - An update	27
Editorial Board	27
Non-oestrogen-based and complementary therapies for menopause	26
Acquired disorders of phosphaturia: Beyond tumor-induced osteomalacia	25

Metabolic complications and their mechanisms in patients with craniopharyngioma	25
Pathogenic role of Th17 cells in autoimmune thyroid disease and their underlying mechanisms	25
Safety of long-term use of daily and long-acting growth hormone in growth hormone-deficient adults on cancer risk	25